CSS
CNTX icon

Cubist Systematic Strategies’s Context Therapeutics CNTX Stock Holding History

Cubist Systematic Strategies’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,710
Closed -$23.8K – 2948
2024
Q4 		$23.8K Buy
+22,710
New +$39.3K ﹤0.01% 2830

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cubist Systematic Strategies's CNTX Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Context Therapeutics (CNTX) in Q1 2025, closing a stake of 22,710 shares — an estimated $23.8K sold.

Cubist Systematic Strategies first reported a position in CNTX in Q4 2024 and held it in 1 quarter. The position peaked at $23.8K in Q4 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Context Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 22,710 Context Therapeutics shares in Q1 2025, an estimated $23.8K.
  • Cubist Systematic Strategies first reported a position in Context Therapeutics in Q4 2024 and held it in 1 quarter.
  • Cubist Systematic Strategies's Context Therapeutics position peaked at $23.8K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.